Evidence map›Paper›PMID 24678245›Full record

ArticleClinical Medicine Insights. Oncology2014

Hormonal Therapeutics Enzalutamide and Abiraterone Acetate in the Treatment of Metastatic Castration-Resistant Prostate Cancer (mCRPC) Post-docetaxel-an Indirect Comparison.

Pui S Tan, Benjamin Haaland, Alberto J Montero, Christos E Kyriakopoulos, Gilberto Lopes

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical Medicine Insights. Oncology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed, 4 pooled it
2.2field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 4 syntheses or guidelines pooled it, 20 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Article
  6. Review
  7. Article
  8. Factors affecting (223)Ra therapy: clinical experience after 532 cycles from a single institution.European journal of nuclear medicine and molecular imaging · 2016
    Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 3 countries.

Pui S TanHealth Services and Systems Research, Duke-NUS Graduate Medical School, Singapore.
Benjamin HaalandCentre for Quantitative Medicine, Office of Clinical Sciences, Duke-NUS Graduate Medical School, Singapore. ; Department of Statistics and Applied Probability, National University of Singapore, Singapore.
Alberto J MonteroCleveland Clinic, Taussig Cancer Institute, Cleveland, OH, USA.
Christos E KyriakopoulosCleveland Clinic, Taussig Cancer Institute, Cleveland, OH, USA.
Gilberto LopesHospital do Coração Cancer Center (HCor Onco), Brazil. ; Centro Paulista de Oncologia, Brazil. ; Oncoclinicas do Brasil, Brazil. ; Johns Hopkins University, Baltimore, MD, USA.
Cleveland Clinic · USDuke-NUS Medical School · SGCentro de Pesquisas Oncológicas · BR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionThis study aims to make an indirect comparison between enzalutamide and abiraterone acetate for mCRPC post-docetaxel.

methodsA search for published phase 3 trials was performed with PubMed. Indirect comparisons of enzalutamide (AFFIRM) to abiraterone acetate (COU-AA-301) on outcomes overall survival (OS), time to prostate-specific-antigen (PSA) progression, radiographic progression-free survival (PFS), and PSA response were constructed in the context of log-linear regression models.

resultsThere was no statistically significant difference in OS (hazard ratio (HR) 0.85, 95% CI 0.68-1.07). However, there was some evidence that enzalutamide may outperform abiraterone acetate with respect to secondary outcomes: time to PSA progression (HR 0.40, 95% CI 0.30-0.53), radiographic PFS (HR 0.61, 95% CI 0.50-0.74), and PSA response rates (RRs) (OR 10.69, 95% CI 3.92-29.20).

conclusionWhile there was no statistically significant difference in OS, enzalutamide may be advantageous for secondary endpoints. Findings of this indirect comparison serve to be hypothesis-generating for future head-to-head trials.

Indexed as

abiraterone acetateenzalutamidemCRPCmetastatic castration-resistant prostate cancerpost-docetaxel

Identifiers

PMID24678245
PMCPMC3964205
OpenAlexW1983214048

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.